Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Theriva Biologics Inc. (TOVX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
01/09/2026: TOVX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -85.94% | Avg. Invested days 13 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 01/09/2026 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 7.83M USD | Price to earnings Ratio 0.11 | 1Y Target Price 7 |
Price to earnings Ratio 0.11 | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.34 | 52 Weeks Range 0.17 - 2.03 | Updated Date 01/9/2026 |
52 Weeks Range 0.17 - 2.03 | Updated Date 01/9/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -29.21% | Return on Equity (TTM) -166.96% |
Valuation
Trailing PE 0.11 | Forward PE - | Enterprise Value 3181795 | Price to Sales(TTM) - |
Enterprise Value 3181795 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 1.72 | Shares Outstanding 35688349 | Shares Floating 33000407 |
Shares Outstanding 35688349 | Shares Floating 33000407 | ||
Percent Insiders 2.07 | Percent Institutions 1.27 |
Upturn AI SWOT
Theriva Biologics Inc.
Company Overview
History and Background
Theriva Biologics Inc. (formerly known as Silverback Therapeutics) was founded in 2014 and rebranded to Theriva Biologics in October 2023. The company is a biopharmaceutical company focused on developing innovative antibody-drug conjugates (ADCs) for the treatment of serious diseases. Significant milestones include its IPO in 2021 and strategic pivots in its pipeline and branding.
Core Business Areas
- Oncology Drug Development: Theriva Biologics is dedicated to the research and development of novel antibody-drug conjugates (ADCs) targeting various types of cancer. Their primary focus is on leveraging targeted therapies to deliver potent cytotoxic agents directly to cancer cells, aiming to minimize systemic toxicity.
Leadership and Structure
The leadership team includes key executives responsible for scientific research, clinical development, operations, and finance. The company operates with a typical biopharmaceutical organizational structure, emphasizing R&D, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- Theriva Biologics Pipeline (Proprietary ADCs): Theriva Biologics is developing a pipeline of novel ADCs. Specific details on market share, revenue, and direct competitors for individual pipeline candidates are not yet publicly available as they are in various stages of preclinical and clinical development. Competitors in the broader ADC space include companies like Seagen (now Pfizer), AbbVie, AstraZeneca, and Daiichi Sankyo.
Market Dynamics
Industry Overview
The antibody-drug conjugate (ADC) market is a rapidly growing segment within the oncology therapeutics sector. Driven by advancements in targeted therapy and drug delivery, ADCs offer a promising approach to treating various cancers with improved efficacy and reduced side effects. The industry is characterized by significant R&D investment, strategic partnerships, and a competitive landscape with both established pharmaceutical giants and emerging biotechnology firms.
Positioning
Theriva Biologics is positioned as an emerging player in the ADC space, aiming to differentiate itself through proprietary ADC technologies and novel therapeutic targets. Its competitive advantage lies in its scientific expertise in ADC design and its focus on developing best-in-class therapies.
Total Addressable Market (TAM)
The total addressable market for oncology therapeutics, particularly for novel targeted agents like ADCs, is substantial and continues to grow. While specific TAM figures for Theriva's niche are proprietary and evolving, the broader ADC market is projected to reach tens of billions of dollars in the coming years. Theriva Biologics aims to capture a significant share of this market by addressing unmet medical needs in oncology.
Upturn SWOT Analysis
Strengths
- Proprietary ADC technology platform
- Experienced scientific and management team
- Focus on a high-growth therapeutic area (oncology ADCs)
Weaknesses
- Early-stage pipeline with no approved products
- Reliance on external funding and capital markets
- Limited commercialization experience
Opportunities
- Growing demand for targeted cancer therapies
- Potential for strategic partnerships and collaborations
- Advancements in drug delivery and conjugation technologies
Threats
- Intense competition in the ADC market
- Regulatory hurdles and clinical trial failures
- Patent expirations and generic competition for other oncology drugs
- Financing challenges for early-stage biotechs
Competitors and Market Share
Key Competitors
- Seagen Inc. (acquired by Pfizer) (SGEN)
- AbbVie Inc. (ABBV)
- AstraZeneca PLC (AZN)
- Daiichi Sankyo Company, Limited (DSNKY)
Competitive Landscape
Theriva Biologics faces a competitive landscape populated by established pharmaceutical companies and agile biotech firms with significant experience and resources in the ADC space. Its advantages lie in its focused pipeline and potentially novel conjugation technologies, while disadvantages include its smaller scale, limited capital compared to larger players, and the inherent risks of early-stage drug development.
Growth Trajectory and Initiatives
Historical Growth: Historically, Theriva Biologics has experienced growth in its R&D activities and pipeline expansion since its inception. The rebranding and strategic shifts also represent milestones in its growth trajectory.
Future Projections: Future growth projections are heavily dependent on the successful progression of its ADC candidates through clinical trials, regulatory approvals, and eventual commercialization. Analyst estimates are contingent on these developmental milestones.
Recent Initiatives: Recent initiatives include the rebranding to Theriva Biologics, strategic adjustments to its pipeline, and ongoing efforts to advance its lead ADC candidates.
Summary
Theriva Biologics Inc. is an early-stage biopharmaceutical company with a focused strategy on developing innovative antibody-drug conjugates for oncology. Its strengths lie in its proprietary technology and dedicated team, while its weaknesses include its unproven pipeline and reliance on external funding. The company has significant opportunities in the growing ADC market but faces intense competition and regulatory risks. Continued progress in its clinical trials and successful fundraising will be critical for its future success.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Industry Analyst Reports
- Company Investor Relations Websites
Disclaimers:
This analysis is based on publicly available information and may not be exhaustive. Financial data and market share figures are estimates and subject to change. Investing in early-stage biotechnology companies involves significant risks. This is not financial advice; consult with a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Theriva Biologics Inc.
Exchange NYSE MKT | Headquaters Rockville, MD, United States | ||
IPO Launch date 2006-12-18 | CEO, CFO, Treasurer, Corporate Secretary & Director Mr. Steven A. Shallcross CPA | ||
Sector Healthcare | Industry Biotechnology | Full time employees 20 | Website https://therivabio.com |
Full time employees 20 | Website https://therivabio.com | ||
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.